108.00
前日終値:
$108.00
開ける:
$108.61
24時間の取引高:
11.95M
Relative Volume:
1.33
時価総額:
$136.94B
収益:
$28.73B
当期純損益:
$5.97B
株価収益率:
22.74
EPS:
4.75
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
-1.19%
1か月 パフォーマンス:
+5.37%
6か月 パフォーマンス:
+19.09%
1年 パフォーマンス:
+71.02%
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
GILD
Gilead Sciences Inc
|
108.00 | 136.94B | 28.73B | 5.97B | 9.84B | 4.75 |
![]()
LLY
Lilly Eli Co
|
785.03 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
150.73 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
NVO
Novo Nordisk Adr
|
74.01 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
![]()
ABBV
Abbvie Inc
|
185.49 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
115.96 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | 再開されました | BofA Securities | Buy |
2024-11-15 | 開始されました | Wolfe Research | Outperform |
2024-11-14 | 開始されました | Citigroup | Buy |
2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-10-17 | 開始されました | Bernstein | Outperform |
2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
2024-05-01 | 繰り返されました | Maxim Group | Buy |
2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
2024-02-22 | ダウングレード | Truist | Buy → Hold |
2023-11-09 | 開始されました | Deutsche Bank | Hold |
2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
2023-09-06 | 開始されました | HSBC Securities | Reduce |
2023-07-24 | 繰り返されました | Barclays | Equal Weight |
2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2023-04-28 | 再開されました | Piper Sandler | Overweight |
2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2022-12-13 | 再開されました | BofA Securities | Neutral |
2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
2022-10-28 | 繰り返されました | Cowen | Outperform |
2022-10-28 | 繰り返されました | JP Morgan | Overweight |
2022-10-28 | 繰り返されました | Jefferies | Buy |
2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
2022-10-28 | アップグレード | Truist | Hold → Buy |
2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
2022-02-02 | 繰り返されました | BofA Securities | Neutral |
2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
2022-02-02 | 繰り返されました | Truist | Hold |
2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
2022-01-28 | アップグレード | Argus | Hold → Buy |
2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
2021-12-06 | 開始されました | Goldman | Neutral |
2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2021-11-19 | 再開されました | Piper Sandler | Neutral |
2021-10-20 | 再開されました | Cowen | Outperform |
2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
2021-03-30 | アップグレード | Redburn | Neutral → Buy |
2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
2020-10-28 | 開始されました | UBS | Neutral |
2020-09-30 | 再開されました | Jefferies | Buy |
2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
2020-07-31 | 繰り返されました | SunTrust | Hold |
2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2020-05-26 | アップグレード | SunTrust | Sell → Hold |
2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
2020-04-27 | ダウングレード | UBS | Buy → Neutral |
2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
HIV advance: Twice-yearly shot to prevent infection - NZ Herald
Gilead's twice-yearly PrEP drug is cleared by FDA - Pharmaphorum
US approves Gilead's twice-yearly injection to prevent HIV - Citizen Tribune
US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News
FDA approves 6-month HIV prevention shot - The Hill
Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus
FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus
Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK
Mizuho says Gilead Yeztugo label looks clean - TipRanks
Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's
FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News
FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com
FDA Approves Gilead’s Twice-Yearly Injectable Yeztugo (Lenacapavir) for HIV Prevention - ContagionLive
Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - Proactive financial news
Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - marketscreener.com
Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus
FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com
Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus
Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus
US FDA approves Gilead's twice-yearly injection for HIV prevention - Reuters
Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia
US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com
Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada
Gilead stock gains on FDA nod for HIV PrEP drug (GILD:NASDAQ) - Seeking Alpha
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC
FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention - marketscreener.com
Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award - CSRwire
Buy, Sell, Or Hold GILD Stock? - Trefis
Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com
Gilead's HIV drug could end epidemic, but the company has a dark side - Fast Company
Insider Sell: Andrew Dickinson Sells 2,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: ReportGilead Sciences (NASDAQ:GILD) - Benzinga
Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern - Insider Monkey
Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud - ACCESS Newswire
GILD ALERT: Levi & Korsinsky Investigates Gilead Sciences, Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Gilead lays off 36 people after axing California expansion plan - Fierce Biotech
Gilead Sciences: Strong HIV Market Position and Diversified Growth Strategy Justify Buy Rating - TipRanks
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD) - ACCESS Newswire
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities Investigation - ACCESS Newswire
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline (NASDAQ:GILD) - Seeking Alpha
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey - Insider Monkey
Gilead Stock Drops After FDA Halts HIV Treatment Trials Over Safety Concerns - Daily Chhattisgarh News
Gilead (GILD) Stock Dips in Trading, But 72% Yearly Gain Highlights Powerful Uptrend - Daily Chhattisgarh News
Transcript : Gilead Sciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11 - marketscreener.com
Optimistic Outlook for Gilead Sciences Driven by Lenacapavir’s Market Potential - TipRanks
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - MSN
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Mercier Johanna | Chief Commercial Officer |
Jun 16 '25 |
Sale |
110.17 |
3,000 |
330,510 |
120,168 |
大文字化:
|
ボリューム (24 時間):